Single tablet combo of macitentan and tadalafil receives US FDA approval for pulmonary artery hypertension
USA: A single-tablet combination of macitentan and tadalafil (Opsynvi) has received approval from the US Food and Drug Administration (FDA) as the first treatment for patients with pulmonary arterial hypertension. OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be […]